Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 6/20 | 0.80 |
| ▸ | HTR2C known ✓ | P28335 | 6/20 | 0.80 |
| ▸ | HTR2B known ✓ | P41595 | 5/20 | 0.80 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.80 |
| ▸ | HTR1D known ✓ | P28221 | 3/20 | 0.80 |
| ▸ | DRD1 known ✓ | P21728 | 3/20 | 0.80 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.80 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.80 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.80 |
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.80 |
| ▸ | HTR1B known ✓ | P28222 | 2/20 | 0.80 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.80 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 0.80 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.80 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.80 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.80 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.80 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.70 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078621 | 0.99 | HTR2A (1.00) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL13701274 | 0.91 | HTR2A (0.84) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL22118461 | 0.90 | HTR2A (0.83) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL5968621 | 0.90 | HTR2A (1.00) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL5968525 | 0.88 | HTR2A (0.79) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL13701275 | 0.82 | HTR2A (0.71) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL22118484 | 0.81 | HTR2A (0.69) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL6603889 | 0.80 | HTR2A (0.68) | HTR2AGRM2HTR7HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL9362999 | 0.78 | HTR2A (0.71) | HTR2AGRM2HTR7HTR2CHTR2B | |
| SCHEMBL14495114 | 0.77 | HTR2A (0.64) | HTR2AGRM2HTR7HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1362589-B1 | Use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMA INC (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1937265-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1289527-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1(2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL OR ITS PRODRUG TO TREAT DEMENTIA OR COGNITIVE IMPAIRMENT | AVENTIS PHARMA INC (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007024599-A2 | COMINATION OF A HYPNOTIC AGENT AND R(+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-7132433-B2 | Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of behavioral or psychological symptoms associated with a disease | AVENTIS PHARMACEUTICALS INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20050272773-A1 | Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-08 | — | — | US | disclosed |
| US-6939879-B2 | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia | AVENTIS PHARMACEUTICALS INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204457-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis | AVENTIS PHARMACEUTICALS INC. | 2004-10-14 | — | — | US | disclosed |
| US-20040002516-A1 | Use of R (+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders | AVENTIS PHARMACEUTICALS INC. | 2004-01-01 | — | — | US | disclosed |
| EP-0796619-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders | MERRELL PHARMACEUTICALS INC. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5618824-A | ADMINISTERING N-ARALKYL PIPERIDINEMETHANOL DERIVATIVES | MERRELL PHARMACEUTICALS INC. (US) | 1997-04-08 | — | — | US | disclosed |
| EP-0749309-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT 2? ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| US-5561144-A | TREATMENT OF SCHIZOPHRENIA | MERRELL PHARMACEUTICALS INC. (US) | 1996-10-01 | — | — | US | disclosed |
| WO-1995024194-A1 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDERS WITH 5-HT2 ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0531410-B1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMA (US) | 1994-11-30 | — | — | EP | disclosed |
| EP-0531410-A4 | (+)--G(A)-(2,3-DIMETHOXYPHENYL)-1- 2-(4-FLUOROPHENYL)ETHYL)-4-PIPERIDINEMETHANOL | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0531410-A1 | (+)-ALPHA-(2,3-DIMETHOXYPHENYL)-1-[2-(FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL. | MERRELL DOW PHARMA (US) | 1993-03-17 | — | — | EP | disclosed |
| US-5134149-A | Serotonin antagonist | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-07-28 | — | — | US | disclosed |
| WO-1991018602-A1 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002516-A1 | Use of R (+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders | PNMT, HCRTR2, EBP | HTR2A 128/4885HTR7 82/4885HTR2C 58/4885 |
| US-20050272773-A1 | Use of R (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-flurophenyl)-ethyl]-4- piperidinemethanol for the treatment of sleep disorders and process for making pharmaceutical composition | OPRD1, EBP, ADRA1D | HTR2A 139/4885HTR7 87/4885HTR2C 78/4885 |
| US-20040204457-A1 | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis | COMT, PNMT, DBH | HTR2A 34/4885HTR7 68/4885HTR2C 15/4885 |
| US-20080139615-A1 | COMBINATION OF A HYPNOTIC AGENT AND R (+)-ALPHA-(2,3-DIMETHOXY-PHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL AND THERAPEUTIC APPLICATION THEREOF | HCRTR2, OPRD1, HCRTR1 | HTR2A 47/4885HTR7 108/4885HTR2C 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.